GT Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-7.6	-20.88	-58.01	-28.3	-38.65	-259.19	-144.17	9.77	-21.43
Depreciation & Amortization	0	0	0	0	0	0.01	0	0	0
Share-Based Compensation	2.2	7.65	33.93	0.27	5.31	9.7	130.12	6.59	3.76
Other Operating Activities	-3.46	-1.98	8.48	20.77	29.68	238.81	8.62	-18.29	13.01
Operating Cash Flow	-8.85	-15.22	-15.61	-7.26	-3.66	-10.68	-5.43	-1.93	-4.66
Capital Expenditures	0	0	0	0	0.2	-0.04	-0	0	-0
Change in Investments	-2.01	12.15	-23.04	0	0	0	0	0	0
Investing Cash Flow	-2.01	12.15	-23.04	0	0.2	-0.04	-0	0	-0
Share Issuance / Repurchase	6.27	0	41.11	0	0	0	0	0	0
Debt Issued / Paid	0	0	1.21	12.53	3.43	10.73	5.99	1.9	3.85
Other Financing Activities	-	-0.22	-	-	-	-0.53	-	-	-
Financing Cash Flow	6.27	-0.22	42.32	12.53	3.43	10.2	5.99	1.9	3.85
Net Cash Flow	-4.59	-3.3	3.67	5.27	-0.03	-0.52	0.56	-0.03	-0.81
Free Cash Flow	-8.85	-15.22	-15.61	-7.26	-3.46	-10.71	-5.43	-1.93	-4.66
Free Cash Flow Margin	-	-	-	-	-	-	-	-	-17251.85%
Free Cash Flow Per Share	-6.57	-14.32	-16.63	-49.68	-30.66	-108.75	-165.27	-12083.27	-992.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).